

1 April 2026

**Total Voting Rights and Notification of Admission of Further Securities to Trading  
(PRM 1.6.4R)**

***Total Voting Rights***

The following notification is made in accordance with the UK Financial Conduct Authority's Disclosure and Transparency Rule 5.6.1. As at 31 March 2026 the issued share capital of AstraZeneca PLC with voting rights is 1,550,980,823 ordinary shares of US\$0.25. No shares are held in Treasury. Therefore, the total number of voting rights in AstraZeneca PLC is 1,550,980,823.

The above figure for the total number of voting rights may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, AstraZeneca PLC under the UK Financial Conduct Authority's Disclosure and Transparency Rules.

***Notification of Admission of Further Securities to Trading (PRM 1.6.4R)***

The following notification is made in accordance with The Public Offers and Admissions to Trading Regulations 2024 (POATRs) PRM 1.6.4R.

|          |   |   |
|----------|---|---|
| <b>1</b> | <b>Details of the issuer</b>                                      |   |
| a)       | Name  | AstraZeneca PLC   |
| b)       | LEI   | PY6ZZQWO2IZFZC3IOL08  |
| <b>2</b> | <b>Details of the transferable securities admitted to trading</b> |   |
| a)       | Name, type and identification code                                | Ordinary Shares of \$0.25 each<br>ISIN: GB0009895292  |
| b)       | Regulated market  | London Stock Exchange - Main Market   |
| c)       | Number of further securities issued and admitted                  | 491   |
| d)       | Total number of securities in issue following admission           | 1,550,980,823   |
| e)       | Fungibility   | Fully fungible with existing Ordinary Shares  |
| <b>3</b> | <b>Admission details</b>  |   |
| a)       | Date of admission   | Issued between 20 March 2026 to 31 March 2026 (admitted under a block admission dated 29 January 2021)                            |
| b)       | Prospectus information  | Prospectus: N/A<br>Supplementary: N/A<br>Company's webpage: <a href="https://www.astrazeneca.com">https://www.astrazeneca.com</a> |

|    |                          |  |
|----|--------------------------|--|
| c) | Coverage of notification | Admission of shares under the Company's employee share schemes from 20 March 2026 up to 31 March 2026, admitted to trading on the Main Market of the London Stock Exchange under the Company's existing block admission of shares dated 29 January 2021. |
|----|--------------------------|--|

### **AstraZeneca**

AstraZeneca (LSE/STO/NYSE: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca's innovative medicines are sold in more than 125 countries and used by millions of patients worldwide. Please visit [astrazeneca.com](https://astrazeneca.com) and follow the Company on social media [@AstraZeneca](https://twitter.com/AstraZeneca)

### **Contacts**

For details on how to contact the Investor Relations Team, please click [here](#). For Media contacts, click [here](#).

**Matthew Bowden**  
**Company Secretary**  
**AstraZeneca PLC**

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [rns@lseg.com](mailto:rns@lseg.com) or visit [www.rns.com](http://www.rns.com).